晚期前列腺癌管理:2019年晚期前列腺癌共识会议报告
2019年晚期前列腺癌共识会议(APCCC)由72位国际专家针对10个争议领域提出123个预设问题,采用改良Delphi流程匿名投票。投票结果基于专家意见而非系统评价,旨在为高级别证据稀疏的临床决策提供参考,并强调个体化治疗与临床试验入组。
要点
- 共识投票覆盖局部晚期、生化复发、转移性激素敏感及去势抵抗等10个争议领域。
- 投票结果反映专家意见,不能替代高级别证据,临床决策需个体化。
- 应鼓励晚期前列腺癌患者参加临床试验,并识别需专门试验评估的问题。
核心结论
- 专家小组的投票结果可帮助临床医生和患者应对高级别证据稀疏的晚期前列腺癌争议领域。
- 诊断和治疗决策应始终基于患者特异性因素、当前及新兴临床证据以及后勤和经济限制进行个体化。
- 应强烈鼓励晚期前列腺癌男性参加临床试验。
研究设计与样本
- 专家小组确定了10个关于晚期前列腺癌管理的重要争议领域。
- 由72位国际前列腺癌专家组成的小组制定了会议计划和共识问题。
- 小组对123个预设问题进行了公开但匿名的投票,问题在会议前由投票和非投票成员按改良Delphi流程制定。
主要发现
- 共识问题的答案选项获得了小组不同程度的支持,详见本文和补充材料中的详细投票结果。
- 投票结果基于专家意见而非标准文献综述或正式荟萃分析。
关键数值与推荐
- 专家小组确定了10个争议领域:局部晚期疾病、局部治疗后生化复发、转移性设置中原发肿瘤的治疗、转移性激素敏感/初治前列腺癌、非转移性去势抵抗性前列腺癌、转移性去势抵抗性前列腺癌、骨骼健康与骨转移、组织和血液的分子特征、患者间和患者内异质性、激素治疗的不良反应及其管理。
- 小组对123个预设问题进行了投票。
临床怎么用
- 投票结果可作为实用指南,帮助临床医生与患者讨论治疗选择,作为共享和多学科决策的一部分。
- 诊断和治疗决策应个体化,考虑疾病范围和位置、既往治疗线数、合并症、治疗偏好以及当前和新兴临床证据。
- 应强烈鼓励晚期前列腺癌男性参加临床试验。
局限性
- 专家小组的投票基于意见而非标准文献综述或正式荟萃分析。
- 共识问题的答案选项支持程度不一,反映在本文和补充材料中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence. OBJECTIVE: To present the results from the APCCC 2019. DESIGN, SETTING, AND PARTICIPANTS: Similar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process. RESULTS AND LIMITATIONS: Panellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material. CONCLUSIONS: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials. PATIENT SUMMARY: The Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making.
引用
- Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020. PMID: 32001144. doi:10.1016/j.eururo.2020.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。